Biomarker Testing and Clinical Trial Enrollment in NSCLC: Retrospective Analysis of Racial Disparities

June 4-8, 2021; Online at https://conferences.asco.org/am
Multivariable regression analyses of deidentified health record data showed that Black patients with NSCLC were less likely to receive NGS-based genetic testing or enroll on clinical trials than White patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 465 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Zofia Piotrowska, MD, MHS, and Karen L. Reckamp, MD, MS, review key data from studies of NSCLC presented at ASCO 2021, as reported by Clinical Care Options (CCO)

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 20, 2021 Expired: August 19, 2022

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings